Myomo, Inc.·Healthcare
Myomo, Inc., a wearable medical robotics company, designs, develops, and produces myoelectric orthotics for people with neuromuscular disorders in the United States. The company offers MyoPro, a myoelectric-controlled upper limb brace or orthosis product used for supporting a patient's weak or paralyzed arm to enable and improve functional activities of daily living. Its products are designed to help improve function in adults and adolescents with neuromuscular conditions due to brachial plexus injury, stroke, traumatic brain injury, spinal cord injury, and other neurological disorders. The company sells its products to orthotics and prosthetics providers, the Veterans Health Administration, and rehabilitation hospitals, as well as through distributors. Myomo, Inc. was incorporated in 2004 and is headquartered in Boston, Massachusetts.
Healthcare
Medical - Devices
184
2017-06-12
1.16

Myomo, Inc. (MYO) Q4 2025 Earnings Call Transcript

Myomo, Inc. (MYO) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to a loss of $0.01 per share a year ago.

BURLINGTON, Mass.--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today reported financial results for the three months and year ended December 31, 2025. “We delivered 2025 revenue at the midpoint of our updated guidance range with record fourth quarter revenues from the U.S. orthotics and prosthetics ("O&P") and Int.

BURLINGTON, Mass.--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, announced today it has entered into its first among a series of expected network participation agreements with Elevance Health. The contracts, which include the Anthem-affiliated Commercial, Medicare Advantage, and Medicaid plans are expected to become eff.

BURLINGTON, Mass.--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that it will report financial results for the fourth quarter and year ended December 31, 2025 on Monday, March 9, 2026. Management will hold a conference call beginning at 4:30 p.m. Eastern time to review the results, provide a business upd.

Myomo (NYSEAMERICAN:MYO - Get Free Report) will likely be announcing its Q4 2025 results before the market opens on Monday, March 9th. Analysts expect Myomo to post earnings of ($0.09) per share and revenue of $10.4030 million for the quarter. Parties may visit the the company's upcoming Q4 2025 earning results page for the latest